Copaxone (Glatiramer Acetate)
Immunomodulatory treatment for relapsing-remitting multiple sclerosis
Quick facts about Copaxone
Key takeaways about Copaxone
- Disease-modifying therapy for MS: Copaxone reduces the number of relapses in relapsing-remitting multiple sclerosis by modulating the immune system
- Daily subcutaneous injection: One 20 mg injection under the skin each day, rotating between seven injection areas to minimize site reactions
- Injection site reactions are very common: Redness, pain, swelling, and itching at the injection site occur frequently but typically decrease over time
- Can cause serious allergic reactions: Anaphylaxis-type reactions may occur even months or years after starting treatment — seek emergency care for breathing difficulties, facial swelling, or widespread rash
- May be used during pregnancy if advised by a doctor: Limited data suggests Copaxone can be used during pregnancy and breastfeeding when recommended by a healthcare provider
What Is Copaxone and What Is It Used For?
Copaxone (glatiramer acetate) is an immunomodulatory medicine prescribed for the treatment of relapsing-remitting forms of multiple sclerosis (MS). It works by modifying how the immune system functions to reduce the frequency of MS relapses in patients who can walk independently.
Multiple sclerosis is a chronic neurological condition in which the body's immune system mistakenly attacks the protective myelin sheath that surrounds nerve fibers in the brain and spinal cord. This leads to the formation of small areas of inflammation and scarring (sclerosis), which can disrupt the normal flow of electrical impulses along the nerves. The result is a wide range of neurological symptoms that characterize the disease.
Copaxone belongs to a class of medicines known as immunomodulators. Rather than broadly suppressing the immune system, glatiramer acetate works by shifting the balance of immune cells from pro-inflammatory responses to anti-inflammatory responses. Specifically, it promotes a shift from Th1-type immune cells (which drive inflammation) to Th2-type cells (which produce anti-inflammatory signals). This mechanism helps protect the myelin sheath from ongoing immune-mediated damage.
The medicine is used primarily to reduce the number of relapses (also called exacerbations or flare-ups) in people with relapsing-remitting MS. A relapse is a distinct episode of new or worsening neurological symptoms that lasts at least 24 hours. It is important to understand that Copaxone has not been shown to help patients with non-relapsing or minimally relapsing forms of MS, and its effect on the duration or severity of individual relapses has not been established.
Copaxone may also be prescribed for patients who have experienced their first clinical episode suggestive of MS and who are considered to be at high risk of developing clinically definite multiple sclerosis. Before initiating treatment in these cases, the prescribing physician will rule out other conditions that could explain the symptoms.
Copaxone is a long-term treatment that must be taken consistently to be effective. It does not cure multiple sclerosis, but it can significantly reduce the frequency of relapses when used as directed. The full benefit of treatment may take several months to become apparent. Do not stop taking Copaxone without first consulting your neurologist.
How does glatiramer acetate work in the body?
Glatiramer acetate is a synthetic polypeptide composed of four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine. These are the same amino acids found in myelin basic protein, a key component of the nerve-insulating myelin sheath. Because of this structural similarity, glatiramer acetate is thought to act as a decoy, diverting the immune attack away from actual myelin.
When injected subcutaneously, glatiramer acetate interacts with immune cells at the injection site and in nearby lymph nodes. Over time, it promotes the development of regulatory T cells and anti-inflammatory cytokines, helping to dampen the autoimmune response that drives MS progression. Research published in the Multiple Sclerosis Journal has confirmed that glatiramer acetate exerts neuroprotective effects in addition to its immunomodulatory properties.
What Should You Know Before Taking Copaxone?
Do not use Copaxone if you are allergic to glatiramer acetate or any of its ingredients. Tell your doctor about kidney or heart problems, liver disease, and all other medications you take. Copaxone is not recommended for children under 12 years of age.
Contraindications
Copaxone must not be used if you are allergic (hypersensitive) to glatiramer acetate or to any of the other ingredients in the product. The other ingredients include mannitol and water for injections. If you have previously experienced a severe allergic reaction to Copaxone or any glatiramer acetate product, you should not use this medicine again.
Warnings and Precautions
Before starting treatment with Copaxone, you should discuss the following with your healthcare provider to ensure the medicine is safe and appropriate for you:
Allergic reactions: Copaxone can cause serious allergic reactions, some of which may be life-threatening. These reactions can occur shortly after an injection or even months to years after starting treatment, including in patients who previously tolerated the injections without problems. Signs and symptoms of allergic reactions may overlap with other post-injection reactions, which can make them difficult to distinguish. Your doctor will explain the warning signs to watch for.
Kidney or heart problems: If you have existing kidney disease or cardiovascular conditions, you may require more frequent monitoring while using Copaxone. Your doctor will assess whether additional check-ups are needed based on your individual situation.
Liver problems: Cases of liver injury, including liver failure requiring transplantation, have been reported rarely with Copaxone. If you have a history of liver disease, including problems related to alcohol consumption, tell your doctor before starting treatment. Seek immediate medical attention if you develop symptoms such as nausea, loss of appetite, dark-colored urine, pale stools, yellowing of the skin or eyes, or unusual bruising or bleeding.
Children: Copaxone should not be used in children under 12 years of age, as safety and efficacy have not been established in this age group.
Elderly patients: Copaxone has not been specifically studied in older adults. If you are elderly, discuss the potential benefits and risks with your neurologist.
- Widespread rash (red spots or hives)
- Swelling of the eyelids, face, lips, mouth, throat, or tongue
- Sudden difficulty breathing, wheezing, or chest tightness
- Seizures (fits)
- Difficulty swallowing or speaking
- Fainting, severe dizziness, or collapse
These may be signs of a severe allergic reaction that requires immediate treatment. Find your emergency number →
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to have a baby, discuss your Copaxone treatment with your doctor before continuing or starting the medicine. Based on available data, Copaxone may be used during pregnancy on the advice of your physician, who will evaluate the benefits and risks for your individual situation.
Limited data from breastfeeding mothers and their infants have not shown any negative effects of Copaxone on the breastfed child. Copaxone may be used by breastfeeding mothers when recommended by their healthcare provider. Always follow your doctor's guidance regarding the use of any medicine during pregnancy and breastfeeding.
Driving and Using Machines
It is not known whether Copaxone affects the ability to drive or operate machinery. You are responsible for assessing whether you are fit to drive a motor vehicle or perform tasks that require alertness. As with any medicine, consider whether you experience side effects that could impair your ability to concentrate before undertaking such activities.
How Does Copaxone Interact with Other Drugs?
No formal drug interaction studies have been conducted with Copaxone. Tell your doctor about all medicines you take, including prescription drugs, over-the-counter medicines, and herbal supplements. Copaxone may interact with corticosteroids used at the injection site.
Although no specific drug interactions have been identified in clinical studies, it is important to inform your doctor or pharmacist about all medications you are currently taking, have recently taken, or might take. This includes prescription medicines, over-the-counter products, vitamins, and herbal supplements.
Because Copaxone is an immunomodulatory agent, theoretical interactions may exist with other medicines that affect the immune system. Your neurologist will take your complete medication profile into consideration when prescribing Copaxone.
| Drug / Category | Type of Interaction | Clinical Significance | Recommendation |
|---|---|---|---|
| Corticosteroids (systemic) | May affect immune modulation | Moderate | Can be used during relapses; discuss with neurologist |
| Other immunomodulators (e.g., interferons) | Overlapping immune effects | Moderate | Not typically combined; consult specialist |
| Immunosuppressants (e.g., azathioprine, methotrexate) | Additive immunosuppressive effects | Moderate | Requires careful medical supervision |
| Vaccines (live attenuated) | Possible reduced vaccine efficacy | Low | Discuss vaccination timing with your doctor |
Copaxone is injected subcutaneously and has a localized mechanism of action at the injection site. Avoid applying topical corticosteroid creams or other medicated products directly at the injection site immediately before or after your Copaxone injection, as this may affect local absorption.
What Is the Correct Dosage of Copaxone?
The recommended dose is one pre-filled syringe (20 mg glatiramer acetate) injected subcutaneously once daily. Always follow your doctor's instructions. Rotate injection sites among seven areas daily. Each syringe is for single use only.
Always use Copaxone exactly as your doctor has prescribed. If you are unsure about how to use your medicine, consult your doctor or pharmacist for clarification. It is essential to maintain consistency with your daily injections to achieve the best possible therapeutic effect.
Adults and Adolescents (12 years and older)
Standard Dosage
Dose: 20 mg (one pre-filled syringe containing 1 ml solution)
Route: Subcutaneous injection (under the skin)
Frequency: Once daily
Duration: Long-term treatment as directed by your neurologist
Children Under 12 Years
Copaxone is not recommended for use in children under 12 years of age. Safety and efficacy have not been established in this population.
Elderly Patients
No specific dosage adjustment is recommended for elderly patients. However, Copaxone has not been specifically studied in this population. Your doctor will determine whether the medicine is appropriate for you based on your overall health and other medications.
Injection Technique and Site Rotation
Proper injection technique is crucial for both the effectiveness of Copaxone and your comfort. There are seven possible injection areas, and you should choose a different area each day to minimize the risk of injection site reactions:
- Area 1 — Abdomen: The area around your navel, avoiding 5 cm (2 inches) directly around it
- Areas 2 and 3 — Thighs: The front of both thighs, above your knees
- Areas 4 and 5 — Upper arms: The back of both upper arms
- Areas 6 and 7 — Hips: The upper, back part of both hips, below your waist
Within each injection area, there are multiple specific injection sites. Choose a new spot within the area each day to allow previously used sites time to heal. It is recommended to keep a rotation schedule and daily injection diary. Some areas, such as the back of the arms, may require assistance from another person.
Do not inject into areas that are painful, discolored, or where you can feel lumps or bumps. If the solution in the syringe contains particles, do not use it — take a new syringe instead. If your syringe has been refrigerated, remove it from the packaging at least 20 minutes before injection to allow it to reach room temperature. Each pre-filled syringe is for single use only.
Missed Dose
If you forget to take your daily Copaxone injection, take it as soon as you remember. However, do not take a double dose to make up for a missed one. Take your next dose 24 hours after the missed dose, and resume your normal injection schedule from that point.
Overdose
If you have accidentally used more than the prescribed amount of Copaxone, or if someone else has inadvertently received the medicine, contact your doctor, hospital, or local poison control center immediately for an assessment of risk and advice on further management.
Stopping Copaxone suddenly may increase your risk of MS relapses. Always discuss any changes to your treatment plan with your neurologist before making adjustments.
What Are the Side Effects of Copaxone?
The most common side effects of Copaxone are injection site reactions (redness, pain, swelling, itching), infections, headache, anxiety, depression, joint pain, and weakness. Serious but rare side effects include allergic reactions (anaphylaxis), liver problems, and immediate post-injection reactions with chest pain or breathing difficulties.
Like all medicines, Copaxone can cause side effects, although not everyone experiences them. Most side effects are mild to moderate and manageable. Injection site reactions are the most frequently reported and tend to decrease over time as your body adjusts to the treatment.
Serious side effects requiring immediate medical attention
Allergic reactions (anaphylaxis): Serious allergic reactions to Copaxone are uncommon but can be life-threatening. They may occur shortly after injection or even months to years after starting treatment, even if previous injections were tolerated without problems. Stop using Copaxone and seek emergency medical care immediately if you experience widespread rash, swelling of the face or throat, sudden breathing difficulties, seizures, difficulty swallowing, fainting, or collapse.
Immediate post-injection reaction: Uncommonly, some patients may experience a cluster of symptoms within minutes of injecting Copaxone. These typically resolve within 30 minutes but include flushing of the chest or face, shortness of breath, chest pain, and rapid heartbeat. If these symptoms persist beyond 30 minutes, seek medical attention immediately.
Liver problems: In rare cases, Copaxone has been associated with liver injury, including liver failure that has led to liver transplantation. Contact your doctor immediately if you notice nausea, loss of appetite, dark urine, pale stools, yellowing of the skin or eyes, or unusual bleeding or bruising.
Side effects by frequency
Very Common
- Infections, flu-like symptoms
- Anxiety, depression
- Headache
- Feeling unwell (malaise)
- Skin rash
- Joint pain, back pain
- Weakness, fatigue
- Injection site reactions: redness, pain, bruising, itching, swelling, inflammation, hypersensitivity
- Non-specific pain
Common
- Respiratory tract inflammation, gastroenteritis, mouth ulcers, ear infection, runny nose, dental abscess, vaginal yeast infection
- Benign skin growths (neoplasms)
- Swollen lymph nodes, allergic reactions
- Loss of appetite, weight gain, nervousness
- Altered taste, increased muscle tension, migraine, speech difficulties, fainting, tremor
- Double vision, eye problems, ear problems
- Cough, hay fever
- Rectal problems, constipation, dental cavities, indigestion, difficulty swallowing, fecal incontinence, vomiting
- Abnormal liver tests
- Bruising, excessive sweating, itching, skin conditions, hives
- Neck pain
- Urinary urgency, frequent urination, urinary retention
- Chills, facial swelling, decreased tissue under the skin at injection site, localized reactions, fluid retention (edema), fever
Uncommon
- Abscess, skin and soft tissue infection, shingles, kidney inflammation
- Skin cancer
- Increased or decreased white blood cell count, enlarged spleen, low platelet count
- Enlarged or overactive thyroid
- Low alcohol tolerance, gout, high blood lipid levels
- Unusual dreams, confusion, euphoria, hallucinations, aggressive behavior, personality changes, suicide attempt
- Carpal tunnel syndrome, seizures (convulsions), difficulty reading or writing, involuntary eye movements, paralysis, foot drop
- Cataracts, corneal ulcers, dry eyes, eye bleeding, drooping eyelid
- Extra heartbeats, slow heartbeat, intermittent palpitations
- Varicose veins
- Periodic breathing interruptions, nosebleeds, hyperventilation, throat tightness
- Bowel inflammation, colon polyps, esophageal ulcers, gum inflammation, rectal bleeding, enlarged salivary glands
- Gallstones, enlarged liver
- Skin and soft tissue swelling, contact eczema, painful red skin nodules
- Joint swelling and pain (arthritis, osteoarthritis), joint inflammation, flank pain, decreased muscle mass
- Blood in urine, kidney stones, urinary problems
- Breast swelling, erectile dysfunction, persistent erection, prostate problems
- Cysts, low body temperature (hypothermia), tissue damage at injection site, non-specific inflammation
Rare
- Severe allergic reactions (anaphylaxis)
- Liver failure (in some cases requiring transplantation)
- Serious skin reactions
If you experience any side effects, including those not listed here, tell your doctor or pharmacist. You can also report suspected side effects directly to your national pharmacovigilance authority. By reporting side effects, you help provide more information about the safety of this medicine.
How Should You Store Copaxone?
Store Copaxone in a refrigerator at 2-8°C. Pre-filled syringes may be stored at room temperature (15-25°C) for up to one month in the original carton. Do not freeze. Keep out of the reach and sight of children. Protect from light.
Proper storage of Copaxone is essential to maintain the medicine's effectiveness and safety. Follow these guidelines carefully:
- Primary storage: Keep the pre-filled syringes in a refrigerator at 2°C to 8°C (36°F to 46°F)
- Room temperature storage: Syringes may be removed from the refrigerator and stored at 15°C to 25°C (59°F to 77°F) for a single period of up to one month
- If unused after one month at room temperature: Return the syringes to the refrigerator in their original packaging
- Do not freeze: Copaxone must never be frozen. If accidentally frozen, discard the syringe
- Protect from light: Always keep the pre-filled syringes in the outer carton, as the medicine is light-sensitive
- Check expiry date: Do not use Copaxone after the expiry date (EXP) printed on the label and carton. The expiry date refers to the last day of that month
- Inspect before use: Do not use syringes that contain particles. Take a new syringe instead
- Keep out of reach of children: Store all medicines where children cannot access them
Used or expired syringes should be disposed of in a designated sharps container. Do not discard medicines in wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. These measures help to protect the environment.
What Does Copaxone Contain?
Each 1 ml pre-filled syringe of Copaxone contains 20 mg glatiramer acetate (corresponding to 18 mg glatiramer) as the active ingredient. The other ingredients are mannitol and water for injections.
Copaxone is a clear solution without visible particles, presented in individually blister-packed pre-filled syringes made of polyvinyl chloride (PVC).
| Component | Type | Amount per Syringe | Function |
|---|---|---|---|
| Glatiramer acetate | Active ingredient | 20 mg (equivalent to 18 mg glatiramer) | Immunomodulatory agent |
| Mannitol | Excipient | As formulated | Tonicity agent (osmolality adjustment) |
| Water for injections | Excipient | q.s. to 1 ml | Solvent |
Available Pack Sizes
Copaxone is available in the following pack sizes containing pre-filled syringes with 1 ml solution each:
- 7 pre-filled syringes
- 28 pre-filled syringes
- 30 pre-filled syringes
- Multipack containing 3 cartons of 30 pre-filled syringes each (90 syringes total)
Not all pack sizes may be marketed in every country. The marketing authorization holder is TEVA GmbH, Ulm, Germany.
Frequently Asked Questions About Copaxone
Medical References and Sources
This article is based on current medical research and international regulatory documents. All claims are supported by scientific evidence from peer-reviewed sources.
- European Medicines Agency (EMA). "Copaxone — Summary of Product Characteristics." Last updated 2025. Official EU regulatory documentation for glatiramer acetate. Evidence level: Regulatory source.
- U.S. Food and Drug Administration (FDA). "Copaxone (glatiramer acetate injection) — Prescribing Information." Teva Neuroscience, Inc. Complete U.S. prescribing information including clinical trial data and safety information.
- National Institute for Health and Care Excellence (NICE). "Disease-modifying therapies for relapsing-remitting and primary progressive multiple sclerosis." Technology appraisal guidance, 2024. UK clinical guidelines for MS disease-modifying therapies including glatiramer acetate.
- Rae-Grant A, Day GS, Marrie RA, et al. "Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis." Neurology. 2018;90(17):777-788. American Academy of Neurology evidence-based practice guidelines. Evidence level: 1A.
- La Mantia L, Munari LM, Lovati R. "Glatiramer acetate for multiple sclerosis." Cochrane Database of Systematic Reviews. 2010;(5):CD004678. Systematic review of glatiramer acetate efficacy and safety in MS. Evidence level: 1A.
- Ziemssen T, Schrempf W. "Glatiramer acetate: mechanisms of action in multiple sclerosis." International Review of Neurobiology. 2007;79:537-570. Comprehensive review of immunomodulatory mechanisms of glatiramer acetate.
- World Health Organization (WHO). "Atlas of MS." 3rd edition, 2020. Global epidemiology and treatment landscape for multiple sclerosis.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in neurology, clinical pharmacology, internal medicine, and immunology.